Answers are grounded in this paper and cite their sources.
In this phase 2 trial, once-monthly maridebart cafraglutide resulted in substantial weight reduction in participants with obesity with or without type 2 diabetes. (Funded by Amgen; ClinicalTrials.gov number, NCT05669599.).
No takes yet. Share an insight, caveat, or question.
Jastreboff et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: